Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-08-02
2008-10-28
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S008100, C514S007600, C435S069700
Reexamination Certificate
active
07442686
ABSTRACT:
The Rho family GTPases regulates axon growth and regeneration. Inactivation of Rho with C3, a toxin fromClostridium botulinum, can stimulate regeneration and sprouting of injured axons. The present invention provides novel chimeric C3-like Rho antagonists. The invention further provides evidence that these compounds promote repair when applied to the injured mammalian central nervous system, such as the retina. The present invention provide agents which are able to diffuse readily and therefore can promote repair for neurodegenerative disease of the eye, such as macular degeneration. The present invention further provides methods of treating macular degeneration, methods of inhibiting or reducing the rate of subretinal neovascularization and proliferation of neovascular tissue and methods of protecting retinal photoreceptor cell death.
REFERENCES:
Wenzel A. et al., Progress in Retinal and eye Research, 2005, vol. 24(2), pp. 275-306.
Ciardella AP. et al., Ophthalmol. Clin. North Am., Dec. 2002, vol. 15(4), pp. 453-458.
Park H-J. et al., Circ. Res., Jul. 26, 2002, vol. 91, pp. 143-150.
Fawell S. et al., Proc. Natl. Acad. Sci., 1994, vol. 91, pp. 664-668.
Borras, T., Exp. Eye Res., 2003, vol. 76, pp. 643-652.
Garner, A., Trans. Ophthalmol. Soc. U. K., 1975, vol. 95(1): 54-61.
Han et al., J. Mol. Biol., 2001, 305:95-107.
Scholl et al., Mol. Vis., 2007, 13:196-205.
Rattner et al., Nat. Rev., 2006, 7:860-872.
Surgucheva et al., Cell. Nol. Neurobiol., 2005, 2(6):1051- 1066.
Adler et al., Cell death in age-related macular degeneration, Molecular Vision, 1999; 5:31, pp. 31-36.
Curcio et al., Photoreceptor loss in age-related macular degeneration, Invest Ophthalmol Vis Sci, Jun. 1996;37(7):1236-49 (Abstract only).
Fan et al., Differential regulation of A beta42-induced neuronal Clq synthesis and microglial activation,J. Neuroinflammation, 2005, 2:1, pp. 1-13.
Hahn et al., Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and . . . , PNAS, 2004, 101:38, pp. 13850-13855.
Klaver et al., Genetic Association of Apolipoprotein E with Age-Related Macular Degeneration, Am. J. Hum Genet., 1998, 63:200-206.
Medeiros et al., Preservation of Ganglion Cell Layer Neurons in Age-related Macular Degeneration, Investigative Ophthalmology & Visual Science, 2001, 42:3, pp. 795-803.
Vander et al., Growth rate of subretinal newvascularization in age-related macumar degeneration, Ophthalmology, 1989, 96(9), pp. 1422-1426 (Abstract only).
Lasko Dana
McKerracher Lisa
Bioaxone Therapeutique Inc.
Kemmerer Elizabeth C.
Ogilvy Renault LLP
Xie Xiaozhen
LandOfFree
Treatment of macular degeneration with ADP-ribosyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of macular degeneration with ADP-ribosyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of macular degeneration with ADP-ribosyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4001628